AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35764205 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not use vitamin D in the past 30 days)
Number of subjects: 236
Study 33301475 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 106
Study 33301475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 106
Study 33301475 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 106
Study 33081083 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose extract treatment
Number of subjects: 0
Study 33081083 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (induced skin stress response)
Number of subjects: 0
Study 37382230 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based progression (PBP) training
Number of subjects: 36
Study 37382230 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 36
Study 36257349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lipid emulsion containing fish oil
Number of subjects: 206
Study 36257349 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion
Number of subjects: 206
Study 33616606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer drugs with positive reimbursement recommendation
Number of subjects: 104
Study 33616606 — intervention group
Group type: COMPARATOR
Intervention: Cancer drugs with negative reimbursement recommendation
Number of subjects: 104
Study 32065644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) with normal saline instilled into the endotracheal tube.
Number of subjects: 100
Study 32065644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 100
Study 32065644 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 100
Study 34311777 — intervention group
Group type: COMPARATOR
Intervention: Candidate treatment (specific candidates not mentioned)
Number of subjects: 6
Study 32273054 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 142201
Study 32273054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142201
Study 32273054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 142201
Study 32722956 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day thiamin supplements
Number of subjects: 60
Study 32722956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32968994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0
Study 32968994 — intervention group
Group type: COMPARATOR
Intervention: Second ARTA therapy
Number of subjects: 0
Study 34794009 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Communication (BCC) and food vouchers together
Number of subjects: 0
Study 34794009 — intervention group
Group type: COMPARATOR
Intervention: Behavior Change Communication (BCC) alone
Number of subjects: 0
Study 34794009 — intervention group
Group type: COMPARATOR
Intervention: Food vouchers alone
Number of subjects: 0
Study 33571072 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeogo™ exoskeleton
Number of subjects: 24
Study 32898699 — intervention group
Group type: EXPERIMENTAL
Intervention: N-glycans from tissue samples
Number of subjects: 83
Study 32898699 — intervention group
Group type: EXPERIMENTAL
Intervention: N-glycans from serum samples
Number of subjects: 83
Study 32898699 — intervention group
Group type: COMPARATOR
Intervention: N-glycans analysis
Number of subjects: 83
Study 32491907 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized multifractal temporally weighted detrended fluctuation analysis (RMFTWDFA)
Number of subjects: 0
Study 32491907 — intervention group
Group type: COMPARATOR
Intervention: Multifractal temporally weighted detrended fluctuation analysis (MFTWDFA)
Number of subjects: 0
Study 35290101 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 565
Study 35290101 — intervention group
Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 565
Study 35290101 — intervention group
Group type: COMPARATOR
Intervention: Olaparib/Cediranib
Number of subjects: 565
Study 34369452 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental vestibulo-ocular reflex (VOR) adaptation (IVA) training, once daily for 15 minutes over 6 months
Number of subjects: 21
Study 34369452 — intervention group
Group type: COMPARATOR
Intervention: x1 training, once daily for 15 minutes over 6 months
Number of subjects: 21
Study 34369452 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental vestibulo-ocular reflex (VOR) adaptation (IVA) training
Number of subjects: 21
Study 34369452 — intervention group
Group type: COMPARATOR
Intervention: x1 training
Number of subjects: 21
Study 32584828 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to an online platform with personalized suggestions for prosocial actions
Number of subjects: 66
Study 32584828 — intervention group
Group type: COMPARATOR
Intervention: Tracking of daily prosocial behavior
Number of subjects: 66
Study 32584828 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of the platform
Number of subjects: 66
Study 35437302 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association (AHA) diet
Number of subjects: 86
Study 35437302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty Liver in Obesity (FLiO) diet
Number of subjects: 86
Study 35437302 — intervention group
Group type: COMPARATOR
Intervention: AHA and FLiO diets
Number of subjects: 86
Study 35437302 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS) model
Number of subjects: 86
Study 35437302 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic screening and insulin resistance markers
Number of subjects: 86
Study 35437302 — intervention group
Group type: EXPERIMENTAL
Intervention: Models predicting changes on Triglycerides and Glucose (TyG) index and Retinol‐binding protein 4 (RBP4) levels
Number of subjects: 86
Study 34162649 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial unicompartmental arthroplasty
Number of subjects: 143
Study 34162649 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty
Number of subjects: 143
Study 33203635 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Maternal Immunisation strategy (MI4MI)
Number of subjects: 0
Study 35207224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the right dorsolateral prefrontal cortex (n = 14)
Number of subjects: 30
Study 35207224 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n = 16)
Number of subjects: 30
Study 33158419 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face reminder by the GP
Number of subjects: 29
Study 33158419 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital reminders targeted at patients with increased CMD risk
Number of subjects: 29
Study 33158419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending invitations and reminders by e-mail
Number of subjects: 29
Study 33158419 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated materials, information gatherings at the practice, self-management toolkits, reminders by telephone, information letters, local media attention, SMS text reminders
Number of subjects: 29
Study 35852024 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller bottles (37.5cl)
Number of subjects: 260
Study 35852024 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller glasses (290ml)
Number of subjects: 260
Study 34308962 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (increased consumption of cigarettes per day by 1 standard deviation)
Number of subjects: 0
Study 34308962 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 0
Study 34308962 — intervention group
Group type: COMPARATOR
Intervention: Binary smoking status
Number of subjects: 0
Study 32938386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 0.03 mg/kg (diluted to 5 mL)
Number of subjects: 210
Study 32938386 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 210
Study 33870714 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial palmitate appearance (Rapalmitate) in IGT
Number of subjects: 60
Study 33870714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapalmitate from obesity‐associated increase in intracellular lipolysis in IGT
Number of subjects: 60
Study 33870714 — intervention group
Group type: COMPARATOR
Intervention: Rapalmitate from DFA spillover in IGT
Number of subjects: 60
Study 33870714 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral AT DFA trapping in IGT
Number of subjects: 60
Study 33870714 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glycerol appearance in IGT
Number of subjects: 60
Study 36181076 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise program for 12 weeks
Number of subjects: 125
Study 36181076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 125
Study 34601233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (1-hour education session and daily mindfulness exercises during hospitalization)
Number of subjects: 158
Study 34601233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness intervention)
Number of subjects: 158
Study 33370962 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sleeve gastrectomy
Number of subjects: 1
Study 33250216 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended spectrum penicillins during the first trimester
Number of subjects: 359
Study 33250216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extended spectrum penicillins)
Number of subjects: 359
Study 33250216 — intervention group
Group type: COMPARATOR
Intervention: Maternal obesity and diabetes
Number of subjects: 359
Study 33250216 — intervention group
Group type: COMPARATOR
Intervention: History of multiple miscarriages
Number of subjects: 359
Study 34114615 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum inflammatory markers (IL‐1β, ‐2, ‐4, ‐6, ‐8, ‐17 A, ‐17 F, ‐21, ‐22 and ‐23)
Number of subjects: 200
Study 34114615 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum inflammatory markers (IL‐10, ‐12 and GM‐CSF)
Number of subjects: 200
Study 34114615 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum markers (Leptin, adipsin and CRP)
Number of subjects: 200
Study 34114615 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum marker (Resistin)
Number of subjects: 200
Study 34114615 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum markers (Apelin‐36 and adiponectin)
Number of subjects: 200
Study 34626915 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-behavioural intervention (PBI)
Number of subjects: 19
Study 34626915 — intervention group
Group type: COMPARATOR
Intervention: Health education program (Control)
Number of subjects: 19
Study 35045227 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Number of subjects: 74
Study 34793637 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of ropivacaine 0.5% (experimental group)
Number of subjects: 52
Study 34793637 — intervention group
Group type: COMPARATOR
Intervention: 15 mL of ropivacaine 0.5% (control group)
Number of subjects: 52
Study 34546360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 858
Study 34546360 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 858
Study 34546360 — intervention group
Group type: COMPARATOR
Intervention: Clinical remission (defined as SF ≤2.8, AP score ≤1.0)
Number of subjects: 858
Study 34546360 — intervention group
Group type: COMPARATOR
Intervention: Clinical parameters (SF and AP)
Number of subjects: 858
Study 34584203 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD1 treatment
Number of subjects: 81
Study 34171233 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 vaccination schedule (3+1) at ages 2, 3, 4, and 9 months (group A)
Number of subjects: 1201
Study 34171233 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 vaccination schedule (3+0) at ages 2, 3, and 4 months (group B)
Number of subjects: 1201
Study 34171233 — intervention group
Group type: COMPARATOR
Intervention: PCV10 vaccination schedule (2+1) at ages 2, 4, and 9.5 months (group C)
Number of subjects: 1201
Study 34171233 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 vaccination schedule (two-dose) at ages 2 and 6 months (group D)
Number of subjects: 1201
Study 32370765 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) + standard of care (SOC) treatments
Number of subjects: 297
Study 32370765 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) palliative-intent treatments
Number of subjects: 297
Study 34875624 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening whey protein supplement
Number of subjects: 15
Study 34875624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32579616 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional support (measured by DUFSS)
Number of subjects: 593
Study 32579616 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional support (medium vs. low tertile)
Number of subjects: 593
Study 32579616 — intervention group
Group type: EXPERIMENTAL
Intervention: IUVs (less than four)
Number of subjects: 593
Study 32579616 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL perception)
Number of subjects: 593
Study 34098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil + hydration
Number of subjects: 1146
Study 34098771 — intervention group
Group type: COMPARATOR
Intervention: Control (simple hydration treatment)
Number of subjects: 1146
Study 34098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil treatment
Number of subjects: 1146
Study 33571453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognosis-matched care (intervention group)
Number of subjects: 1671
Study 33571453 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus attention control (control group)
Number of subjects: 1671
Study 33571453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognosis-matched care (intervention group) in severe prognostic group
Number of subjects: 1671
Study 33571453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognosis-matched care (intervention group) in severe prognostic group (complier average causal effect analysis)
Number of subjects: 1671
Study 32157623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Information Program for Safer Sex (computer‐tailored intervention)
Number of subjects: 274
Study 35988576 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once-daily
Number of subjects: 0
Study 35988576 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once-daily
Number of subjects: 0
Study 35988576 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once-daily
Number of subjects: 0
Study 35988576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34293127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium DASH diet (1150 mg sodium)
Number of subjects: 412
Study 34293127 — intervention group
Group type: COMPARATOR
Intervention: High-sodium control diet (3450 mg sodium)
Number of subjects: 412
Study 32162310 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 3694
Study 35956264 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable diet (F&V) for 6 months
Number of subjects: 47
Study 35956264 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet) for 6 months
Number of subjects: 47
Study 36276376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) based on clinical parameters (age, race, marital status, TNM stage, tumor size, surgery)
Number of subjects: 3528
Study 36276376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 3528
Study 36276376 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk classification system for patients with pRCC
Number of subjects: 3528
Study 32018065 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 320
Study 32018065 — intervention group
Group type: COMPARATOR
Intervention: Clarification‐oriented psychotherapy
Number of subjects: 320
Study 32018065 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 320
Study 35603908 — intervention group
Group type: EXPERIMENTAL
Intervention: ertugliflozin
Number of subjects: 0
Study 33629508 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat and fast food dietary pattern
Number of subjects: 1401
Study 33629508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish and vegetables dietary pattern
Number of subjects: 1401
Study 33629508 — intervention group
Group type: EXPERIMENTAL
Intervention: Starchy foods dietary pattern
Number of subjects: 1401
Study 32161366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN‐OT) administration (24 IU/day for 4 weeks)
Number of subjects: 38
Study 33812487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir, emtricitabine, and tenofovir alafenamide fumarate
Number of subjects: 643
Study 33812487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 643
Study 33812487 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 643
Study 32023313 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing for 12.2 ± 0.1 h
Number of subjects: 18
Study 32023313 — intervention group
Group type: COMPARATOR
Intervention: Sitting for 14.4 ± 0.3 h
Number of subjects: 18
Study 35358395 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐‐rich beetroot juice (BRnitrate)
Number of subjects: 12
Study 35358395 — intervention group
Group type: COMPARATOR
Intervention: NO3‐‐depleted beetroot juice (BRplacebo)
Number of subjects: 12
Study 33596412 — intervention group
Group type: EXPERIMENTAL
Intervention: WiSE system (leadless endocardial system) for cardiac resynchronization therapy
Number of subjects: 0
Study 33596412 — intervention group
Group type: COMPARATOR
Intervention: Conventional epicardial left ventricular lead (implied control)
Number of subjects: 0
Study 32580161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise training performed twice a week (n = 17)
Number of subjects: 32
Study 32580161 — intervention group
Group type: COMPARATOR
Intervention: Nordic hamstring exercise training performed once a week (n = 15)
Number of subjects: 32
Study 33567883 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Interview Training for Transition Age Youth
Number of subjects: 71
Study 33567883 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 71
Study 32163573 — intervention group
Group type: EXPERIMENTAL
Intervention: High Body Mass Index (BMI)
Number of subjects: 12403
Study 32163573 — intervention group
Group type: COMPARATOR
Intervention: Genetic risk of PCOS
Number of subjects: 12403
Study 32969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 150 mg bid
Number of subjects: 458
Study 32969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 300 mg bid
Number of subjects: 458
Study 32969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 450 mg bid
Number of subjects: 458
Study 32969758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 32969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv (all doses combined)
Number of subjects: 458
Study 32969758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Number of subjects: 458
Study 32474564 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h-SIRI/B (oral S-1 with 24-h infusion of irinotecan plus bevacizumab)
Number of subjects: 120
Study 32474564 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI/B (FOLFIRI plus bevacizumab)
Number of subjects: 120
Study 32474564 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h-SIRI/B
Number of subjects: 120
Study 32474564 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI/B
Number of subjects: 120
Study 35989681 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention for Refugees (FSI‐R)
Number of subjects: 80
Study 35989681 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 80
Study 34454161 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered cesarean (Method 1)
Number of subjects: 129
Study 34454161 — intervention group
Group type: COMPARATOR
Intervention: Traditional cesarean (Method 2)
Number of subjects: 129
Study 32836059 — intervention group
Group type: EXPERIMENTAL
Intervention: With feedback (internal or external)
Number of subjects: 140
Study 32836059 — intervention group
Group type: COMPARATOR
Intervention: Without feedback
Number of subjects: 140
Study 32836059 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCS (Method of Constant Stimuli)
Number of subjects: 140
Study 32836059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive staircase
Number of subjects: 140
Study 34716036 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-led engagement behaviors
Number of subjects: 37
Study 34716036 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-led engagement behaviors
Number of subjects: 37
Study 34716036 — intervention group
Group type: EXPERIMENTAL
Intervention: General engagement behaviors
Number of subjects: 37
Study 33222171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-reduced RBCS
Number of subjects: 50
Study 33222171 — intervention group
Group type: COMPARATOR
Intervention: Gamma-irradiated RBCS
Number of subjects: 50
Study 34613338 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically lower level of non-HDL cholesterol (17 mg/dL)
Number of subjects: 102607
Study 34946289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-1 (IG-1): Complementary training with traditional means of physical therapy
Number of subjects: 97
Study 34946289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-2 (IG-2): Complementary training with mechanical devices
Number of subjects: 97
Study 34946289 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 97